Chemotherapy in brain metastases

Neurosurgery

Volumn 57, Issue 5 SUPPL., 2005, Pages

  Peereboom, David M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Blood brain barrier; Brain metastases; Chemoradiotherapy; Chemotherapy

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IMATINIB; INTERLEUKIN 2; IRINOTECAN; LOMUSTINE; METHOTREXATE; NIMUSTINE; NITROSOUREA DERIVATIVE; PREDNISONE; PROCARBAZINE; TEMOZOLOMIDE; TENIPOSIDE; TIOGUANINE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BONE MARROW TOXICITY; BRAIN CANCER; BRAIN CAPILLARY; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MONOTHERAPY; NEPHROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL; RADIOSURGERY; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 27644440946     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000182740.39014.9A     Document Type: Review

References (125)

1. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53:259-265, 2001.
2. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 22:2101-2107, 2004.
3. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Caspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004.
4. Antonadou D, Coliarakis N, Paraskevaidis M, Athanasiou H, Sarris G, Synodinou M, Skarlatos I, Sagriotis A, Georgakopoulos G, Beroukas C, Karageorgis P, Throuvalas N: Whole brain radiotherapy alone or in combination with temozolomide for brain metastases: A phase III study. Proceedings from the 2002 Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO). Int J Radiat Oncol Biol Phys 54-93-94, 2002.
5. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, Throuvalas N: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650, 2002.
6. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α2B in patients with metastatic melanoma. Clin Cancer Res 8:3075-3081, 2002.
7. Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, Kalofonos C, Skarlos D, Karabelis A, Kosmidis P: Temozolomide in combination with docetaxel in patients with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 20:420-425, 2002.
8. Bafaloukos D, Tsoutsos D, Fountzilas G, Linardou H, Christodoulou C, Kalofonos HP, Briassoulis E, Panagiotou P, Hatzichristou H, Gogas H: The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 14:289-294, 2004.
9. Balis FM, Poplack DG: Central nervous system pharmacology of antileukemic drugs. Am J Pedialr Hematol Oncol 11:74-86, 1989.
10. Batchelor T, Leahy N, Kaufman D: High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma. Clin Lymphoma 2:116-119, 2001.
11. Bernardo G, Cuzzoni Q, Strada MR, Bernardo A, Brunetti G, Jedrychowska I, Pozzi U, Palumbo R: First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study. Cancer Invest 20:293-302, 2002.
12. Black KL, Ningaraj NS: Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 11:165-173, 2004.
13. Black PMcL: Brain tumors. Part 1. N Engl J Med 324:1471-1476, 1991.
14. Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM: Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 41:464-468, 1998.
15. Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195:73-83, 1975.
16. Bocci G, Francia G, Man S, Lawler J, Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100:12917-12922, 2003.
17. Boogerd W, Dalesio O, Bais EM, van der Sande JJ: Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69:972-980, 1992.
18. Boogerd W, van der Sande JJ, van Zandwijk N: Teniposide sometimes effective in brain metastases from non-small cell lung cancer. J Neurooncol 41:285-289, 1999.
19. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-brain Tumor Treatment Group. Lancet 345:1008-1012, 1995.
20. Brem S, Staller A, Wotoczek-Obadia Mea: Interstitial chemotherapy for local control of CNS metastases. Presented at the annual meeting of the Society of Neuro-Oncology, Toronto, ON, Canada, November 18-21, 2004 (abstr).
21. Brooks BJ, Bani JC, Fletcher CD, Demeteri GD: Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571) J Clin Oncol 20:870-872, 2002
22. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL: Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery 51:656-665, 2002.
23. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E: Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol 15:1042-1047, 2004.
24. Cersosimo RJ: Topotecan: A new topoisomerase I inhibiting antineoplastic agent. Ann Pharmacother 32:1334-1343, 1998.
25. Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP: Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47:129-138, 2005.
26. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV: Phase II study of temozolomide in heavily preheated cancer patients with brain metastases. Ann Oncol 12:249-254, 2001.
27. Cloughesy TF, Black KL: Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 26:125-132, 1995.
28. Cloughesy TF, Gobin YP, Black KL, Viñuela F, Taft F, Kadkhoda B, Kabbinavar F: Intra-arterial carboplatin chemotherapy for brain tumors: A dose escalation study based on cerebral blood flow. J Neurooncol 35:121-131, 1997.
29. Cocconi G, Lottici R, Bisagni G, Bacchi M, Tonato M, Passalacqua R, Boni C, Belsanti V, Bassi P: Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 8:327-334, 1990.
30. Colleoni M, Graiff C, Nelli P, Vicario G, Sgarbossa G, Pancheri F, Manente P: Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Am J Clin Oncol 20:303-307, 1997.
31. Colvin DM: Alkylating agents and platinum antitumor compounds, in Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III (eds): Cancer Medicine. Hamilton, BC Decker, Inc., 2003, pp 648-669.
32. Conrad CA: Chemotherapy for metastatic tumors to the central nervous system. Curr Oncol Rep 3:490-494, 2001.
33. Cooper KG, Kitchener HC, Parkin DE: Cerebral metastases from epithelial ovarian carcinoma treated with carboplatin. Gynecol Oncol 55318-323, 1994.
34. Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA: The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 4:110-124, 1998.
35. Davson H: The environment of the neurone. Trends Neurosci 1:39-41, 1978.
36. Donelli MG, Zucchetti M, D'Incalci M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251-260, 1992.
37. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637-647, 2000.
38. Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, Legrand C, Giaccone G: Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: A phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 39:1271-1276, 2003.
39. Edwards MS, Levin VA, Byrd A: Quantitative observations of the subacute effects of X irradiation on brain capillary permeability: Part II. Int J Radiat Oncol Biol Phys 5:1633-1635, 1979.
40. Ewend MG, Brem S, Gilbert M, Goodkin R, Penar P: Treating single brain metastasis with resection, placement of BCNU-polymer wafers, and radiation therapy. Presented at the 72nd Annual Meeting of the American Association of Neurological Surgeons, Toronto, ON, Canada, April 24-26, 2001 (abstr). Available at http://www.aans.org/Library/Artide.aspx?ArtideId=13719. Accessed October 15, 2004.
41. Ewend MG, Hobbs KB: Treatment of recurrent CNS metastases using BCNU-polymer wafers. Presented at the 72nd Annual Meeting of the American Association of Neurological Surgeons, Orlando, Florida, May 1-6, 2004 (abstr).
42. Ford J, Osborn C, Barton T, Bleehen NM: A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 34:1807-1811, 1998.
43. Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 85:1599-1605, 1999.
44. Friedman HS, Evans B, Reardon D, Quinn J, Rich J, Gururangan S, Stafford-Fox V, Chen C, Pati A, Schmidt W: Phase II trial of temozolomide for patients with progressive brain metastases. Proc Am Soc Clin Oncol 102, 2003 (abstr).
45. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K: Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 59:291-295, 2000.
46. Furuse K, Kamimori T, Kawahara M, Kodama N, Ogawara M, Atagi S, Naka N, Akira M, Kubota K: A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomydn in non-small-cell lung cancer with brain metastasis. Br J Cancer 75:614-618, 1997.
47. Gaspar LE, Scott C, Murray K, Curran W: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:1001-1006, 2000.
48. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997.
49. Giannitto-Giorgio C, Cordio S, Di Blasi C: Temozolomide shows promising activity against pretreated brain recurrences of NSCLC. Preliminary results of a phase II trial (abstr). Available at http://www.asco.org/ac/1,1003,_12-002643- 00_18-0016-00_19-002779,00.asp. Accessed January 20, 2005.
50. Giglio P, Tremont-Lukats IW, Groves MD: Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 65:167-172, 2003.
51. Golden GA, Meldorf M, PROLONG Study Group: Patients with metastatic brain cancer, undergoing resection and Gliadel implantation experienced low local recurrence rates in the PROLONG Registry. Presented at the annual meeting of the Society of Neuro-Oncology Toronto, ON, Canada, November 18-21, 2004 (abstr).
52. Gregor A, Lind M, Newman H, Grant R, Hadley DM, Barton T, Osborn C: Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma: RMP-7 European Study Group. J Neurooncol 44:137-145, 1999.
53. Greig NH, Momma S, Sweeney DJ, Smith QR, Rapoport SI: Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 47:1571-1576, 1987.
54. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI: Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol 26:263-268, 1990.
55. Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD, Sampson JH: Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 9:5514-5520, 2003.
56. Grossman SA, Fisher JD, Piantadosi S, Brem H: The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, objectives, and activities. Cancer Control 5:107-114, 1998.
57. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874, 2004.
58. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005.
59. Hwu WJ, Krown SE, Lis E, Menell JH, Panageas KS, Merrell J, Williams LJ, Livingston PO, Wolchok JD, Chapman PB: Phase II study of temozolomide (TMZ) plus thalidomide in patients with brain metastasis from malignant melanoma. Proc Am Soc Clin Oncol 22:720, 2003 (abstr).
60. Hwu WJ, Raizer J, Panageas KS, Lis E: Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2:634-635, 2001.
61. Jarden JO, Dhawan V, Poltorak A, Posner JB, Rottenberg DA: Positron emission tomographic measurement of blood-to-brain and blood-to-tumor transport of 82Rb: The effect of dexamethasone and whole-brain radiation therapy. Ann Neurol 18:636-646, 1985.
62. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA: TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15:1063-1070, 1997.
63. Kelly K, Bunn PA Jr: Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 20:85-91, 1998.
64. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436, 2004.
65. Koehler PJ: Use of corticosteroids in neuro-oncology. Anticancer Drugs 6:19-33, 1995.
66. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schofski P, Derigs G, Ruther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C: First-line high-dose chemotherapy ± radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 11:553-559, 2000.
67. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999.
68. Korfel A, Oehm C, von Pawel J, Keppler U, Deppermann M, Kaubitsch S, Thiel E: Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation: A multicentre phase II study. Eur J Cancer 38:1724-1729, 2002.
69. Kortmann RD, Jeremic B, Weller M, Plasswilm L, Bamberg M: Radiochemotherapy of malignant glioma in adults: Clinical experiences. Strahlenther Onkol 179:219-232, 2003.
70. Lassman AB, Abrey LE, Begemann M, Picconi KJ, Vuksanaj K, Malkin MG, Raizer JJ: Systemic high dose methotrexate (HD MTX) for central nervous system (CNS) metastases. Presented at Annual Meeting of the American Society of Clinical Oncology (abstr 2083). Available at: http://www.asco.org/ac/1,1003,_12- 002636-00_18-0016-00_19-002083,00.asp. Accessed March 10, 2005.
71. Lesniak MS, Brem H: Targeted therapy for brain tumours. Nat Rev Drug Discov 3:499-508, 2004.
72. Lesser GJ: Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin N Am 7:527-536, 1996.
73. Levin VA: Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682-684, 1980.
74. Levin VA, Edwards MS, Byrd A: Quantitative observations of the acute effects of x-irradiation on brain capillary permeability: Part I. Int J Radiat Oncol Biol Phys 5:1627-1631, 1979.
75. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z: Convection-enhanced delivery of paditaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 100:472-479, 2004.
76. Malacarne P, Santini A, Maestri A: Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 53:210-213, 1996.
77. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, Smith W, Dutcher P, Gollob J, Longmate J, Johnson D: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218, 2002.
78. Markesbery WR, Brooks WH, Gupta GD, Young AB: Treatment for patients with cerebral metastases. Arch Neurol 35:754-756, 1978.
79. Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 42:433-440, 1998.
80. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51-60, 2000.
81. Monnell K, Minton S, Phuphanich S: Complete response of intracranial metastatic breast cancer to trastuzumab and vinorelbine following neoadjuvant chemobiotherapy. Neuro-Oncol 352, 2003 (abstr).
82. National Comprehensive Cancer Network: Central Nervous System Cancers Version 1.2003. Available at: http://www.nccn.org/professionals/physician_gls/ PDF/cns.pdf. Accessed April 7, 2005.
83. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org/professionals/physician_gls/ default.asp. Accessed February 20, 2005.
84. Neuwelt EA, Frenkel EP, Rapoport S, Barnett P: Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery 7:36-43, 1980.
85. Newton HB, Slivka MA, Volpi C, Bourekas EC, Christoforidis GA, Baujan MA, Slone W, Chakeres DW: Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol 61:35-44, 2003.
86. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF: Status of high-dose chemotherapy for breast cancer: A review. Biol Blood Marrow Transplant 6:476-495, 2000.
87. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR, Brand R, Hermans J: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29:711-717, 1994.
88. Oberhoff C, Kieback DG, Wurstlein R, Deertz H, Sehouli J, van Soest C, Hilfrich J, Mesrogli M, von Minckwitz G, Staab HJ, Schindler AE: Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study. Onkologie 24:256-260, 2001.
89. Pardridge WM: Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 3:90-105, 2003.
90. Patchell RA: Metastatic brain tumors. Neurol Clin 13:915-925, 1995.
91. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280:1485-1489, 1998.
92. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990.
93. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, Middleton MR: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12:175-178, 2002.
94. Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJ, Karnicka H, Lewinski T, van Meerbeeck J, Clerico M, Gregor A, Curran D, Sahmoud T, Kirkpatrick A, Giaccone G: Treatment of brain metastases of small-cell lung cancer: Comparing teniposide and teniposide with whole-brain radiotherapy-A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18:3400-3408, 2000.
95. Prados MD, Schold SJS, Fine HA, Jaeckle K, Hochberg F, Mechtler L, Fetell MR, Phuphanich S, Feun L, Janus TJ, Ford K, Graney W: A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncol 5:96-103, 2003.
96. Pronzato P, Bruna F, Neri E, Roveri D, Trabucchi A, Vanoli M, Vigani A, Vaira F, Losardo P, Bertelli G: Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer. Anticancer Res 15:517-519, 1995.
97. Qin DX, Zheng R, Tang J, Li JX, Hu YH: Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 19:1507-1510, 1990.
98. Reboul F, Vincent P, Brewer Y, Faure CF, Taulelle M: Chemoradiotherapy for brain metastases of lung origin: Results of a Phase II study. Proc Am Soc Clin Oncol 15:373, 1996 (abstr).
99. Richards JM, Gale D, Mehta N, Lestingi T: Combination of chemotherapy with interleukin-2 and interferon α for the treatment of metastatic melanoma. J Clin Oncol 17:651-657, 1999.
100. Richtig E, Hofmann-Wellenhof R, Pehamberger H, Forstinger C, Wolff K, Mischer P, Raml J, Fritsch P, Zelger B, Ratzinger G, Koller J, Lang A, Konrad K, Kindermann-Glebowski E, Seeber A, Steiner A, Fialla R, Pachinger W, Kos C, Klein G, Kehrer H, Kerl H, Ulmer H, Smolle J: Temozolomide and interferon α2b in metastatic melanoma stage IV. Br J Dermatol 151:91-98, 2004.
101. Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, Bennouna J, Souquet PJ, Balmes P, Thiberville L, Fournel P, Quoix E, Riou R, Rebattu P, Perol M, Paillotin D, Mornex F: Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12:59-67, 2001.
102. Rogers LR, Remer SE, Tejwani S: Durable response of breast cancer leptomeningeal metastasis to capedtabine monotherapy. Neuro-oncol 6:63-64, 2004.
103. Rosner D, Flowers A, Lane WW: Chemotherapy induces regression of brain metastases in breast carcinoma patients: Update study. Proc Am Soc Clin Oncol 12, 1993 (abstr).
104. Rosner D, Nemoto T, Lane WW: Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58:832-839, 1986.
105. Salvati M, Cervoni L, Innocenzi G, Bardella L: Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen: Report of three cases. Tumori 79:359-362, 1993.
106. Siegelmann-Danieli N, Stein M, Bar-Ziv J: Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 5:833-834, 2003.
107. Siena S, Landonio G, Baietta E, Vitali M, Crino L, Danova M, Musolino A, Gardin G, Foa P, Fincato G: Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer. Proc Am Soc Clin Oncol 22:102, 2003 (abstr).
108. Smith QR: Carrier-mediated transport to enhance drug delivery to brain, in de Boer AG (ed): Drug Transport(ers) and the Diseased Brain. International Congress Series 1277. Philadelphia, Elsevier, 2005, pp 63-74.
109. Strauss SI, Marples M, Napier MP, Meyer T, Boxall J, Rustin GJ: A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. Br J Cancer 89:1901-1905, 2003,
110. Takada Y, Greig NH, Vistica DT, Rapoport SI, Smith QR: Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemother Pharmacol 29:89-94, 1991.
111. Takada Y, Vistica DT, Greig NH, Purdon D, Rapoport SI, Smith QR: Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res 52:2191-2196, 1992.
112. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011, 2003.
113. Tosoni A, Ermani M, Brandes AA: The pathogenesis and treatment of brain metastases: A comprehensive review. Crit Rev Oncol Hematol 52:199-215, 2004.
114. Ushio Y, Arita N, Hayakawa T, Mogami H, Hasegawa H, Bitoh S, Oku Y, Ikeda H, Kanai N, Kanoh M: Chemotherapy of brain metastases from lung carcinoma: A controlled randomized study. Neurosurgery 28201-205, 1991.
115. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41:44-48, 1997.
116. van der Gaast A, Alexieva-Figusch J, Vecht C, Verweij J, Stoter G: Complete remission of a brain metastasis to third-line hormonal treatment with megestrol acetate. Am J Clin Oncol 13:507-509, 1990.
117. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY: Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? Oncol Rep 9:683-688, 2002.
118. Verger E, Gil M, Yaya R, Vinolas N, Villa S, Pujol T, Solano MV, Arribas L, Grau F: Concomitant temozolomide (TMZ) and whole brain radiotherapy (WBRT) in patients with brain metastases (BM): Randomized multicentric phase II study. Proc Am Soc Clin Oncol 22:101, 2003 (abstr).
119. Vick NA, Bigner DD: Micro vascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. J Neurol Sci 17:29-39, 1972.
120. Vick NA, Khandekar JD, Bigner DD: Chemotherapy of brain rumors. Arch Neurol 34:523-526, 1977.
121. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, Heiss WD, Jacobs AH: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54:479-487, 2003.
122. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL: Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 24:421-424, 2001.
123. Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Rommell F, Pan H, Hingorani VN, Puri RK: Local convection enhanced delivery of IL4-pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88:93-103, 2003.
124. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z: A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5:79-88, 2003.
125. Zimatore M, Danova M, Vassallo E, Porta C, Macaluso MC, Schittone L, Riccardi A, Palmeri S: Weekly taxanes in metastatic breast cancer (review). Oncol Rep 9:1047-1052, 2002.